vascular endothelial News
-
TransVaginal Female Sexual and SUI Treatment
The first of three already conducted clinical pilots, relate to using MoreNova for female Sexual Improvement and Stress Urinary Incontinence. The pilots presented at the International Continence Society (ICS) 2021 Melbourne conference. Treatment was offered to women suffering from stress urinary incontinence, sexual dysfunction or both conditions. Initial results are highly encouraging. Low ...
By DirexGroup
-
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®. The product will be marketed under the proprietary name ALYMSYS® and represents the third bevacizumab biosimilar ...
By mAbxience
-
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, ...
-
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the ...
-
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2a Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply ...
-
Ocular diseases and the rise of Biologics in the field of Ophthalmology
Speaking at the American Academy of Optometry 2021 annual meeting in Boston, Anthony DeWilde, OD, FAAO, discussed biologics, which hold promise for the treatment of ophthalmic diseases. Original Post can be read here. A wide range of articles cover the use of biologics in oncology. Apart from oncology, biologics have been successful in various therapeutic indications as listed in Annexure A. ...
By Qprotyn Inc
-
Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company was pleased to announce the launch of its Cancer Cytokines Assay, assisting in the detection of multiple cytokine ...
-
Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on diseases of the eye, announced positive interim data from the ongoing open-label Phase I/II FOCUS clinical trial of its investigational one-time gene therapy, GT005, in people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were presented today in an ...
-
Why we need to drink hydrogen water and where can i buy hydrogen water
Olansi Healthcare Co., Ltd(Guangzhou Olans Water Treatment Equipments Co. Ltd) is a professional manufacturer in producing hydrogen water products,including hydrogen water maker,hydrogen water machine,hydrogen water filter,hydrogen water generators and hydrogen water bottle. hydrogen water maker In our life,many people now more focus on their health.like water,many people choose hydrogen ...
-
Why we need to drink hydrogen water and where can i buy hydrogen water
Olansi Healthcare Co., Ltd(Guangzhou Olans Water Treatment Equipments Co. Ltd) is a professional manufacturer in producing hydrogen water products,including hydrogen water maker,hydrogen water machine,hydrogen water filter,hydrogen water generators and hydrogen water bottle.hydrogen water makerIn our life,many people now more focus on their health.like water,many people choose hydrogen water.Does ...
-
AVEO Oncology Highlights Recent Progress and 2022 Outlook
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. “I am proud of the entire AVEO team this year, as we accomplished several key milestones in the face of what remains a challenging environment with the ongoing COVID-19 pandemic,” said Michael Bailey, President and Chief Executive ...
-
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC: HMTXF; FRA:2VFO) is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer. Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is ...
-
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors AVEO Oncology (Nasdaq: AVEO), a commercial stage, ...
-
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and clinical studies in additional cardiovascular ...
-
Bayer receives positive CHMP opinion for Eylea in the EU for treatment of preterm infants with retinopathy of prematurity
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
By Bayer AG
-
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in ...
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 ...
By Bayer AG
-
Study findings offer a promising new direction for organ regeneration and tissue repair
Researchers identify a novel approach to enhance tissue growth Because most human tissues do not regenerate spontaneously, advances in tissue repair and organ regeneration could benefit many patients with a wide variety of medical conditions. Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Dana-Farber/Boston Children’s Cancer and Blood ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you